The biochemistry of rapid replication
Replikins Logo



35. Flu Pandemic Warning Company sets up in UK March 25, 2010

BioRadar to set up HQ in Britain

March 25, 2010 - A company that predicts the strain of future flu outbreaks has revealed it will open its ground-breaking European base in the UK.

BioRadar, which is run by a Canadian and US husband and wife, develops synthetic vaccines to counter the type of flu predicted.

The inward investment is a major boost to the UK's life sciences sector.

Dr Samuel Bogoch and Dr Elenore Bogoch decided to set up Bioradar on UK shores having been helped by the UK Trade & Investment's Global Entrepreneurs Programme (GEP) over the last six years.

Dr Samuel Bogoch said: "The UK is the ideal place for BioRadar's European HQ. There is a life sciences sector which is among the very best in the world. It also brings us closer to potential customers both in the UK and in Europe.

"We are confident that our company can grow faster over the next few years from the UK."

The company successfully predicted the outbreak to the H1N1 swine flu outbreak last year after years of collecting and analysing data.

Dr Bogoch said: "The recent high-profile public concern over the bird flu and swine flu outbreaks have underscored the need for the best possible advanced surveillance in dealing with these potentially devastating outbreaks. We now have more than 10 years of data showing the accuracy of BioRadar."

Lord Davies, Minister for Trade, Investment and Small Business, said: "BioRadar is ideally suited to the UK."

"Britain has the perfect location, the world-class skills and access to the world's markets to help a company grow and prosper."

UK Trade and Investment article

Learn more  

Dr. Sanjay Gupta of CNN reports on Replikins

Synthetic flu vaccine option?

2009 report on Replikins and the potential of synthetic vaccine technology to improve on traditional vaccine approaches.


The Science:
Replikins in H1N1


A recent Nature Precedings paper shows the location of Replikins peptides on the surface of the active Hemagglutinin portion of the H1N1 virus.